Ixabepilone

被引：51

作者：

Conlin, Alison

Fornier, Monica

Hudis, Clifford

Kar, Santwana

Kirkpatrick, Peter

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Breast Canc Med Serv, New York, NY USA

[2] IMS Hlth, London NW1 6JB, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2007年 / 6卷 / 12期

关键词：

D O I：

10.1038/nrd2469

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Ixabepilone (Ixempra; Bristol-Myers Squibb), a cytotoxic microtubule inhibitor, was approved by the US FDA for the treatment of metastatic breast cancer in October 2007. It is the first member of the epothilone family of anticancer agents to be approved.

引用

页码：953 / 954

页数：2

共 15 条

[1]

Baselga J, 2005, BREAST CANCER RES TR, V94, pS31

[2] Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer [J].

Blum, JL ;

Jones, SE ;

Buzdar, AU ;

LoRusso, PM ;

Kuter, I ;

Vogel, C ;

Osterwalder, B ;

Burger, HU ;

Brown, CS ;

Griffin, T .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :485-493

[3]

BOLLAG DM, 1995, CANCER RES, V55, P2325

[4] Targeting the microtubules in breast cancer beyond taxanes: The epothilones [J].

Cortes, Javier ;

Baselga, Jose .

ONCOLOGIST, 2007, 12 (03) :271-280

[5]

*FDA, FDA LAB INF

[6] Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer [J].

Fumoleau, P ;

Largillier, R ;

Clippe, C ;

Dièras, V ;

Orfeuvre, H ;

Lesimple, T ;

Culine, S ;

Audhuy, B ;

Serin, D ;

Curé, H ;

Vuillemin, E ;

Morère, JF ;

Montestruc, F ;

Mouri, Z ;

Namer, M .

EUROPEAN JOURNAL OF CANCER, 2004, 40 (04) :536-542

[7] Microtubules as a target for anticancer drugs [J].

Jordan, MA ;

Wilson, L .

NATURE REVIEWS CANCER, 2004, 4 (04) :253-265

[8]

Lee FYF, 2001, CLIN CANCER RES, V7, P1429

[9]

Perez EA, 2007, J CLIN ONCOL, V25, P3407, DOI 10.1200/JCO.2006.09.3849

[10]

Pivot X, 2006, ANN ONCOL, V17, P70

← 1 2 →